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The trends of the antioxidant drug “U-74389G”  
on potassium levels during hypoxia reoxygenation  
injury in rats
Abstract
Background: This experimental study examined the trends of the anti-
oxidant drug “U-74389G”, on a rat model and particularly in a hypoxia 
– reoxygenation (HR) protocol. The trends of that molecule were studied 
biochemically using blood mean potassium levels.
Methods: 40 rats of mean weight 231.875 g were used in the study. 
Potassium (K+) levels were measured at 60 min of reoxygenation (groups A 
and C) and at 120 min of reoxygenation (groups B and D) with administra-
tion of the drug U-74389G in groups C and D.
Results: U-74389G administration non significantly decreased the K+ 
levels by 2.14%+5.06% (p= 0.6730). Reoxygenation time non-significant-
ly increased the K+ levels by 8.66%+4.85% (p= 0.0934). However, U-
74389G administration and reoxygenation time together non-significantly 
increased the K+ levels by 2.07%+3.03% (P= 0.4853).
Conclusions: U-74389G administration, reoxygenation time and their 
interaction have miscellaneous non significant short – term trends on potas-
sium levels. Perhaps, a longer study time or a higher drug dose may reveal 
clearer and significant effects.
IntroductIon
Permanent or transient damage with serious implications on adjacent organs and systems may be due to tissue hypoxia reoxygenation (HR). 
The use of U-74389G in HR has been a challenge for many years. How-
ever, although the progress was significant, several practical questions 
have not been clarified yet. They include: a) how potent U-74389G should 
be b) when should it be administered and c) at what optimal dose U-
74389G should be administered. The promising effect of U-74389G in 
tissue protection has been noted in several HR studies. U-74389G or also 
known as 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-
pregna-1,4,9(11)-triene-3,20-dione maleate salt is an antioxidant which 
prevents both arachidonic acid-induced and iron-dependent lipid per-
oxidation (1). It protects against HR injury in animal organs such as heart, 
liver and kidney models. These membrane-associating antioxidants are 
particularly effective in preventing permeability changes in brain micro-
vascular endothelial cells monolayers (2).
The aim of this experimental study was to evaluate the effect of U-
74389G in a rat model of HR using mean blood potassium (K+) levels. 
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periments with favorable outcomes. Actually, Flessas I et 
al found (3) the U-74389G protective in many emergency 
clinical situations of intestinal IR. Bimpis A et al limited 
brain damage itself after (4) U-74389G administration. 
Tsaroucha AK et al (5) attenuated liver damage after U-
74389G administration. Andreadou I et al protected the 
small intestine (6) after U-74389G administration. Along, 
ovarian TNFa and malondialdehyde levels were evalu-
ated at the same endpoints. The levels of TNFa were 
stayed rather undisturbed; whereas the malondialdehyde 
levels were kept significantly increased. Nevertheless, the 
recommendation was that these 2 body mass related bio-
markers not to be considered because they were not rep-
resentative of all tissues under the ischemia level. Con-
trary, potassium is a systemic variable concerning all these 
tissues and not only the ovaries. The consequence of the 
applied treatment was the investigation of the short-term 
trends of U-74389G on general metabolism and certainly 
whether it is anabolic or catabolic. Table 1 depicts that 
after the evaluation of 18 seric variables, the shost-term 
trend of the drug is rather catabolic; without the potassi-
um trend included. This table was built-up by the succes-
sive stepwise addition of published studies (7–9). Although 
the addition of every variable was incidental, it seems that 
the profil of the table and generally of the drug is improb-
able to change, as many other variables even if be added.
materIals and methods
animal preparation
This basic experimental research was licensed by Vet-
erinary Address of East Attiki Prefecture under 3693/12-
11-2010 & 14/10-1-2012 decisions. All consumables, 
equipment and substances used, were a grant of Experi-
mental Research Centre of ELPEN Pharmaceuticals Co. 
Inc. S.A. at Pikermi, Attiki. Accepted standards of hu-
mane animal care were adopted for Albino female Wistar 
rats. 7 days pre-experimental normal housing included ad 
libitum diet in laboratory. Post-experimental awakening 
and preservation of animals was not permitted even if 
euthanasia was required. Rats were randomly delivered to 
four experimental groups by 10 animals in each one, us-
ing following protocols of HR: Hypoxia for 45 min fol-
lowed by reoxygenation for 60 min (group A). Hypoxia 
for 45 min followed by reoxygenation for 120 min (group 
B). Hypoxia for 45 min followed by immediate U-74389G 
intravenous (IV) administration and reoxygenation for 
60 min (group C). Hypoxia for 45 min followed by im-
mediate U-74389G IV administration and reoxygenation 
for 120 min (group D). The molecule U-74389G dosage 
was 10 mg/Kg body weight of animals.
Prenarcosis preceded of continuous intra-experimental 
general anesthesia, oxygen supply, electrocardiogram and 
Table 1: The U-74389G influence (±SD) on the levels of some seric variables7 concerning reperfusion (rep) time
Variable 1h rep p-value 1.5h rep p-value  2h rep p-value interaction of 
U-74389G and rep 
p-value
WBCC8 +22.99%±53.60% 0.0914 +30.12%±10.87% 0.0050 +37.25%±93.02% 0.0212 +23.64%±6.32% 0.0003
RBCC +1.39%±0.71%  0.7161 +0.64%±0.32% 0.8106  –0.10%±0.05%  0.9762  +1.05%±0.53% 0.4911
Hematocrit9 +5.58%±3% 0.0852 +4.73%±2.25% 0.0435 +3.89±3.44% 0.2608 +3.16%±1.33% 0.0196
Hemoglobin +5.2%±2.8% 0.0925 +3.9%±2.1% 0.0604 +2.7%±3.2% 0.3544 +2.5%±1.3% 0.0423
MCH +1.77%±0.96% 0.0663 +2.40%±0.57% 0.0001 +3.03%±0.71% 0.0003 1.33%±0.36% 0.0005
Platelet count2 –17.79%±9.40% 0.0647 –12.83%±5.79% 0.0303 –7.88%±7.83% 0.2939 –6.12%±3.58% 0.0857
Platelet-crit +3.80%±9.87% 0.6373 +9.23%±6.29% 0.1064 +14.66%±9.03% 0.0833 +6.72%±3.73% 0.0712
PDW +1.1%±0.88% 0.2368 +1.79%±0.76% 0.0314 +2.49%±1.33% 0.0807 +0.96%±0.46% 0.0396
Glucose –6.41%±3.50% 0.0663 –8.57%±2.06% 0.0001 –10.74%±2.52% 0.0003 –4.76%±1.28% 0.0005
Total protein –5.48%±2.99% 0.0663 –7.34%±1.76% 0.0000 –9.20%±2.16% 0.0000 –4.08%±1.10% 0.0000
ALP  +22.66%±12.37% 0.0663 +31.91%±7.69% 0.0001 +41.16%±9.65% 0.0003 +17.75%±4.79% 0.0005
ACP –112.54%±20.95% 0.0006 –128.45%±14.84% 0.0000 –144.36%±21.62% 0.0000 –74.45%±9.63% 0.0000
CPK +54.32%±13.75% 0.0012 +35.34%±17.20% 0.0260 +16.37%±30.24% 0.4951 +18.52%±9.44% 0.0770
Sodium  +1.22%±0.66% 0.0707 +0.17%±0.61% 0.7714  –0.87%±1.03% 0.3995  –0.32%±0.36% 0.3693
Chloride  –0.58%±0.77% 0.4533 –0.97%±0.53%  0.0879 –1.36%±0.76% 0.1113  –0.75%±0.38% 0.0159 
Calcium  0%±1.75% 1  –0.14%±1.10%  0.8782  –0.28%±1.54%  0.8492  +0.14%±0.64% 0.8245
Phosphorus  –2.23%±5.51% 0.7966  –1.61%±3.32%  0.5789  –1%±4.48% 0.8129  –1.09%±2% 0.5771
Magnesium +1.33%±3.59% 0.7033 –0.28%±2.75% 0.9171 –1.90%±5.28% 0.7161 +0.36%±4.58% 0.8228
Mean –1.31%±31.71%  0.2897 –2.22%±34.31%  0.2415 –3.11%±37.99% 0.3030 –0.85%±20.13% 0.1909
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acidometry. Hypoxia was caused by laparotomic clamp-
ing inferior aorta over renal arteries with forceps for 45 
min. Reoxygenation was induced by removing the clamp 
and reestablishment the inferior aorta patency. After ex-
clusion of blood flow, the protocol of HR was applied, as 
described above for each experimental group. U-74389G 
was administered at the time of reoxygenation through 
inferior vena cava catheter. The K+ levels were determined 
at 60th min of reoxygenation (for A and C groups) and at 
120th min of reoxygenation (for B and D groups). Four-
ty female Wistar albino rats were used (mean weight 
231.875 g [standard deviation (SD): 36.59703 g], with 
minimum weight 165 g and maximum weight 320 g. 
Rats’ weight could be potentially a confusing factor, e.g. 
more obese rats to have higher K levels. This assumption 
was also investigated.
control groups
20 control rats (mean mass 252.5 g [SD: 39.31988 g]) 
experienced hypoxia for 45 min followed by reoxygen-
ation.
Group A
Reoxygenation lasted for 60 min (n=10 controls rats) 
mean mass 243 g [SD: 45.77724 g], mean K+ levels 6.85 
mmol/l [SD: 0.8449194 mmol/l] (Table 2).
Group B
Reoxygenation lasted for 120 min (n=10 controls rats) 
mean mass 262 g [SD: 31.10913 g], mean K+ levels 6.82 
mmol/l [SD: 0.9507891 mmol/l] (Table 2).
lazaroid (l) group
20 L rats (mean mass 211.25 g [SD: 17.53755 g] expe-
rienced hypoxia for 45 min followed by reoxygenation in 
the beginning of which 10 mg U-74389G /kg body 
weight were IV administered.
Group C
Reoxygenation lasted for 60 min (n=10 L rats) mean 
mass 212.5 g [SD: 17.83411 g], mean K+ levels 6.19 
mmol/l [SD: 0.3784471 mmol/l] (Table 2).
Group D
Reoxygenation lasted for 120 min (n=10 L rats) mean 
mass 210 g [SD: 18.10463 g], mean K+ levels 7.23 mmol/l 
[SD: 1.040353 mmol/l] (Table 2).
statistical analysis
Every weight and K+ level group was compared with 
each other by statistical standard t-tests (Table 3). Any 
significant difference among K+ levels, was investigated 
whether owed in probable significant weight correlations. 
Table 2: Weight and potassium mean levels and Std. Dev. of groups





















Table 3: Statistical significance of mean values difference for groups (DG) after statistical paired t test application.































C. Tsompos et al. The trends of the antioxidant drug “U-74389G” on potassium levels during hypoxia reoxygenation injury in rats
108 Period biol, Vol 118, No 2, 2016.
The generalized linear models (glm) with dependant 
variable the K+ levels were applied. The 3 independent 
variables were the U-74389G or no drug, the reoxygena-
tion time and both variables in combination. Inserting 
the rats’ weight also as an independent variable at glm 
analysis, a non significant relation resulted in with K+ 
levels (p=0.4029), so as to further investigation was not 
needed.
results
The application of glm analysis resulted in: U-74389G 
administration non significantly decreased the K+ levels 
by 0.125 mmol/l [–0.7032406 mmol/l – 0.4532407 
mmol/l] (P= 0.6641). This finding was in accordance with 
the results of standard t-test (p= 0.6820). Reoxygenation 
time non-significantly increased the K+ levels by 0.505 
mmol/l [–0.0504671 mmol/l – 1.060467 mmol/l] (P= 
0.0735), also in accordance with standard t-test (p= 0.1134). 
However, U-74389G administration and reoxygenation 
time together non-significantly increased the K+ levels by 
0.1209091 mmol/l [–0.2263983 mmol/l – 0.4682165 
mmol/l] (P= 0.4853). Reviewing the above and table 3, 
the figures 1 and 2 sum up concerning the increasing 
trend of U-74389G in connection with reoxygenation 
time.
dIscussIon
Bibliography lacks references concerning whether hy-
poxia can influence the potassium levels. Potassium levels 
influence (10, 11) multiple physiological processes, includ-
Figure 1: The increasing trend of U-74389G on potassium levels regarding reoxygenation time (p-value=0.4853).
 Figure 2: The (%) increasing trend of U-74389G on potassium levels regarding reoxygenation time (p-value=0.4853).
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ing resting cellular-membrane potential and the propaga-
tion of action potentials in neuronal, muscular, and car-
diac tissue (12). Also K influences the hormone secretion 
and action, the vascular tone, controls the systemic blood 
pressure and the gastrointestinal motility. It joins in acid–
base homeostasis, in glucose and insulin metabolism, in 
mineralocorticoid action, in renal concentrating ability 
and in fluid and electrolyte balance. Isolated potassium 
administration is impossible. The reason is that K+ has a 
single electron in its outer electron shell, which readily 
gives it up to create an atom with a positive charge – a 
cation and oxidizes rapidly in air. After oxidation, it reacts 
vigorously with water combining with anions to form 
salts. Potassium occurs only in ionic salts usually associ-
ated with another drug or a factor. This last chemical 
conjugate probably influences the potassium occurrence. 
So, the administration of potassium is by means of a salt. 
Chiu PY et al associated (13) the inhibition of the mito-
chondrial permeability transition through the opening of 
mitochondrial K+(ATP) channels, affording protection 
against myocardial ischemia reperfusion (IR) injury in rat 
myocardium. Kuhrt H et al found (14) that the expression 
of inwardly rectifying K+ (Kir) currents and transient A-
type K+ currents alterations are characteristic features of 
retinal glial (Müller) cells after transient retinal IR. Nos-
saman BD et al associated (15) the vasodilator free radical 
peroxynitrite (ONOO–) with a cGMP–dependent mech-
anism in the hindlimb vascular bed of the cat. Pollesello 
P et al have shown (16) that the protective vasodilatory 
and antiischemic effects are mediated via the opening of 
ATP-sensitive K+ channels in vascular smooth-muscle 
cells and also in mitochondrial ATP-sensitive K+ (mito-
KATP) channels in heart. Chicco AJ et al (17) demon-
strated that resistance to myocardial IR injury is depen-
dent on sarcolemmal K+(ATP) activity during IR in rats. 
García González MJ et al associated (18) the vasodilatory 
effect with ATP-dependent K+ channel K+(ATP) opening 
properties in cardiogenic shock. Bittner HB et a com-
bined (19) the post-transplant increased mortality rate by 
40% with the low-K+ dextran flush solution for the pro-
curement of donor lungs. Reinés A et al found (20) that 
endogenous inhibitor endobain E, was able to inhibit 
both enzyme activity and ligand binding on synapto-
somal membrane Na+K+-ATPase activity, binding to ce-
rebral IR cortex membranes in rats. Müllenheim J et al 
found that ischemic late preconditioning (ILPC) blocks 
(21) K+(ATP) channels and cardioprotection against pro-
longed ischemia in isolated cells of rabbits coronary IR. 
Reshef A et al (22) conferred protection against ATP-
depleting crisis, opening the ATP-sensitive K+(ATP) 
channels in a model of primary rat IR neuronal cultures. 
Schmidt TA et al related the high concentration of 
Na+K+ATPase with large pressure work (23) in animal IR 
myocardium.
Also, K+ levels are perhaps influenced by U-74389G 
administration. Stanimirovic DB et al abolished (24) the 
hydrogen peroxide-evoked decrease in Na,K-ATPase ac-
tivity in presence of the steroid antioxidants U-74389G 
(5–20 μM) in rats cerebromicrovascular endothelial cells 
(RCEC). The oxidant-induced inhibition of Na,K-ATPase 
activity implicate the mechanism responsible for the de-
layed free radical-induced increase in RCEC membrane 
‘permeability’.
conclusIon
U-74389G administration, reoxygenation time and 
their interaction have miscellaneous non significant short 
– term trends on K+ levels. Perhaps, a longer study time 
or a higher U-74389G dosage may reveal clearer and sig-
nificant effects; including also an equal number of male 
rats for probable gender bias exclusion.
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